Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory 1

Interventions

pegaspargase 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Busulfan 2Asparaginase 2tislelizumab 1sugemalimab 1selinexor 1pembrolizumab 1fludarabine 1Vorinostat 1Transplantation 1Tomography, X-Ray Computed 1Sirolimus 1Methylprednisolone 1Methotrexate 1Melphalan 1IMC-001 1Cyclosporine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × Vorinostat × 90 days × Clear all
NCT00336063 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡